Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Novartis discontinues clinical program for anticancer candidate ASA-404

Nov. 12, 2010

Astex's AT-9283 enters phase II trial in multiple myeloma

Nov. 12, 2010

SuperGen discontinues development of SGI-1776 due to toxicity results

Nov. 11, 2010

Eusa Pharma submits BLA to FDA for Erwinase in acute lymphoblastic leukemia

Nov. 11, 2010

Merck KGaA patents new E-NPP 2 inhibitors

Nov. 11, 2010

Omeros identifies GPR87 receptor antagonist that potentiates doxorubicin activity

Nov. 11, 2010

Apogee Biotech to begin phase I ABC-294640 development in several types of cancer

Nov. 10, 2010

Dutch scientists patent new modulators of glycoprotein hormone LH receptor

Nov. 10, 2010

Genta begins phase IIb tesetaxel trial in metastatic breast cancer

Nov. 9, 2010

Aeterna Zentaris identifies new quinaxoline derivatives for cancer therapy

Nov. 9, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...